SCHEMBL16103441

SCHEMBL16103441

Cc1cnc(N)c(-c2noc(C)n2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.40
ATR Q13535 2/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
PRKDC P78527 1/20 0.35
ATM Q13315 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
AOC3 Q16853 2/20 0.35
IDO1 P14902 1/20 0.34
PLK1 P53350 1/20 0.33
RECQL P46063 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NTRK1 P04629 2/20 0.33
PIM1 P11309 2/20 0.33
CHEK1 O14757 1/20 0.33
CDK2 P24941 1/20 0.33
CSNK2A1 P68400 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618443 0.85 ATR (0.40) L3MBTL1ATRCA12CA1CA2
SCHEMBL617697 0.73 MAPT (0.41) ATRCA12CA1CA2CA9
SCHEMBL14927235 0.72 PIK3CG (0.43) ATRPRKDCATMIDO1
SCHEMBL16103366 0.72 ACHE (0.46) ATRATMIDO1
SCHEMBL16597167 0.71 L3MBTL1 (0.44) L3MBTL1CA12CA1CA2CA9
SCHEMBL20489436 0.70 CA12 (0.39) L3MBTL1CA12CA1CA2CA9
SCHEMBL12267166 0.69 L3MBTL1 (0.43) L3MBTL1CA12CA1CA2CA9
SCHEMBL14927231 0.69 IDO1 (0.32) IDO1
SCHEMBL14927227 0.67 ATR (0.36) ATR
SCHEMBL21028436 0.67 NTRK1 (0.42) L3MBTL1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365557-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 US disclosed
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-29 US disclosed
US-8841308-B2 Pyrazin-2-amines useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-23 US disclosed
US-20100222318-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222318-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 L3MBTL1 3422/4885ATR 1/4885CA12 4536/4885
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 L3MBTL1 3422/4885ATR 1/4885CA12 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.